- Home
- YYAI vs ABP Comparison
YYAI vs ABP Comparison
Compare YYAI & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- ABP
- Stock Information
- Founded
- YYAI 2015
- ABP 2004
- Country
- YYAI Hong Kong
- ABP United States
- Employees
- YYAI N/A
- ABP N/A
- Industry
- YYAI
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- YYAI
- ABP Health Care
- Exchange
- YYAI NYSE
- ABP Nasdaq
- Market Cap
- YYAI 12.1M
- ABP 12.1M
- IPO Year
- YYAI N/A
- ABP N/A
- Fundamental
- Price
- YYAI $0.96
- ABP $0.32
- Analyst Decision
- YYAI
- ABP Strong Buy
- Analyst Count
- YYAI 0
- ABP 1
- Target Price
- YYAI N/A
- ABP $4.00
- AVG Volume (30 Days)
- YYAI 244.5K
- ABP 223.3K
- Earning Date
- YYAI 03-24-2025
- ABP 05-18-2025
- Dividend Yield
- YYAI N/A
- ABP N/A
- EPS Growth
- YYAI N/A
- ABP N/A
- EPS
- YYAI N/A
- ABP N/A
- Revenue
- YYAI N/A
- ABP $183,000.00
- Revenue This Year
- YYAI N/A
- ABP N/A
- Revenue Next Year
- YYAI N/A
- ABP N/A
- P/E Ratio
- YYAI N/A
- ABP N/A
- Revenue Growth
- YYAI N/A
- ABP 50.00
- 52 Week Low
- YYAI $0.35
- ABP $0.23
- 52 Week High
- YYAI $21.60
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- YYAI 63.56
- ABP N/A
- Support Level
- YYAI $0.70
- ABP N/A
- Resistance Level
- YYAI $0.90
- ABP N/A
- Average True Range (ATR)
- YYAI 0.09
- ABP 0.00
- MACD
- YYAI 0.02
- ABP 0.00
- Stochastic Oscillator
- YYAI 90.75
- ABP 0.00
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.